DKA at T1D diagnosis is associated with worsening glycemic control over time, independent of demographic, socioeconomic and treatment‐related factors and baseline fasting C‐peptide (Peditric Dibetes)
Diabetes News
Glycosmedia is dedicated to bringing free, non-promotional, editorially independent news to a global audience about developments in diabetes, and is primarily aimed at health professionals.
Pregabalin in the Management of Painful Diabetic Neuropathy: A Narrative Review
This review evaluates the role of pregabalin in the management of pDPN as well as its potential adverse effects, such as somnolence and dizziness, which can lead to withdrawal in ~ 30% of long-term use (Diabetes Therapy)
Intermediate Diabetes Outcomes in Patients Managed by Physicians, Nurse Practitioners, or Physician Assistants: A Cohort Study
No clinically significant variation was found among the 3 PCP types with regard to diabetes outcomes, suggesting that similar chronic illness outcomes may be achieved by physicians, NPs, and PAs (Annals of Internal Medicine)
Physical exercise and non‐insulin glucose‐lowering therapies in the management of Type 2 diabetes mellitus: a clinical review
To date there is limited understanding of the interactions between oral/injectable agents and engagement in physical activity in people at risk or already living with Type 2 diabetes. The results of the present review lead us to advocate physical exercise for people at risk of developing or already with Type 2 diabetes whilst using drug monotherapy, with some caveats (Diabetic Medicine)
Helicobacter pylori eradication improves glycemic control in type 2 diabetic patients with asymptomatic active Helicobacter pylori infection
Diabetic patients with active Helicobacter pylori infection need higher glycemic treatment intensity to achieve comparable glycemia. Furthermore, Helicobacter pylori eradication decreases A1C, and thus improves glycemic control (JDI)
6-year change in resting heart rate is associated with incident type 2 diabetes mellitus
Dynamic RHR change was significantly associated with incident T2DM. Our study suggests that RHR may be a non-invasive clinical indicator for interventions aiming to reduce incident T2DM in the general population (NMCD)
Perioperative Diabetes: High and Lows
This NCEPOD report highlights the quality of diabetes care for patients aged 16 years or older who underwent a surgical procedure. The report takes a critical look at areas where the care of patients might have been improved. Remediable factors have also been identified in the clinical and the organisational care of these patientsNational Confidential Enquiry into Perioperative Deaths (NCEPOD)
Applicability of telemedicine in the screening of diabetic retinopathy (DR): The first multicentre study in Italy. The No Blind Study
Our findings, in an Italian setting, confirm main data in the literature about DR prevalence. Hence, telemedicine could represent an accurate, fast and cheap method for screening of DR (Diabetes/Metabolism Research and Reviews)
The effects of incretin‐based therapies on beta‐cell function and insulin resistance in type 2 diabetes: a systematic review and network meta‐analysis combining 360 trials
Incretin‐based therapies not only show an increase of HOMA‐β and fasting C‐Peptide level, but also achieve a reduction of HOMA‐IR and FPG in comparison with placebo. Even though GRADE evidences indicate low to moderate for most comparisons, incretin‐based therapies seem to be advisable option for long term treatment to obtain preservation of β‐cell function (Diabetes, Obesity and Metabolism)
How Representative are the Patients Included in the CV outcome Trials with SGLT2 Inhibitors of a General Type 2 Diabetes Population?
In large T2D populations from Europe, consistent patterns of representativeness for CVOTs were found when applying main enrollment criteria. DECLARE‐TMI 58 showed the highest representativeness, indicating that it includes and examines patients who are most representative of the general T2D patient in the studied countries (Diabetes, Obesity and Metabolism)
Investigating the Association Between Baseline Characteristics (HbA1c and Body Mass Index) and Clinical Outcomes of Fast-Acting Insulin Aspart in People with Diabetes
In participants with T1D and T2D, treatment differences (for change in HbA1c and overall hypoglycaemia) between mealtime faster aspart and insulin comparators were similar to the corresponding overall analysis across baseline HbA1c and BMI subgroups. The finding of a lower total daily insulin dose in participants with obesity (BMI > 30 kg/m2) and T1D treated with faster aspart, versus those treated with IAsp, may warrant further investigation (Diabetes Therapy)
Effects of intensive interventions compared to standard care in people with type 2 diabetes and microalbuminuria on risk factors control and cardiovascular outcomes
Apart from blood pressure outcomes, there was no evidence that intensive interventions improve or worsen HbA1c, total cholesterol, LDL, triglycerides, urinary albumin excretion rate, risk of cardiovascular or mortality outcomes in people with type 2 diabetes and microalbuminuria. Results of this review are mainly influenced by one small trial, hence uncertainty surrounding the effect of intensive interventions in people with type 2 diabetes and microalbuminuria still exists. Large studies are urgently required in this high risk cardiovascular group of patients (Diabetes Research and Clinical Practice)
Assessment of Self-monitoring of Blood Glucose in Individuals With Type 2 Diabetes Not Using Insulin
No statistical difference between patients who do not self-monitor their blood glucose multiple times per day and those who do self-monitor their blood glucose multiple times per day in glycemic control, nor evidence of effects on health-related quality of life, patient satisfaction, or decreased number of hypoglycemic episodes (JAMA)
HbA1c screening in the community: Lessons for safety and quality management of a point of care programme
POC testing must be conducted within stringent quality assurance processes prior to and while in use. Within such a system, POC testing for HbA1c can be sufficiently accurate for screening and diagnosis of diabetes (Primary Care Diabetes)
Commencing insulin glargine 100 U/mL therapy in people with type 2 diabetes: Determinants of achievement of HbA1c goal <7.0%
Baseline HbA1c was the strongest determinant for achieving target HbA1c <7.0% by supplementary Gla‐100 therapy while sex and BMI were also useful indicators. However, age and C‐peptide levels at baseline did not predict glycaemic response to the introduction of basal insulin (Diabetes, Obesity and Metabolism)
Non-traditional biomarkers and incident diabetes in the Diabetes Prevention Program: comparative effects of lifestyle and metformin interventions
The findings strengthen evidence linking adiponectin to diabetes development, and argue against a central role for endothelial dysfunction. The findings have implications for the pathophysiology of diabetes development and its prevention (Diabetologia)
A systematic review on costs and cost-effectiveness of screening and prevention of type 2 diabetes in women with prior gestational diabetes: exploring uncharted territory
An oral glucose tolerance test per three years leads to the lowest cost per case detected, and prevention is potentially cost-effective or cost-saving. More health economic evaluations are needed that compare all relevant alternatives, including ‘doing nothing’ (Diabetes Research and Clinical Practice)
Sliding scale insulin for non‐critically ill hospitalised adults with diabetes mellitus
Based on low‐ to very low‐certainty evidence, our results for non‐critically ill hospitalised adults with diabetes mellitus in the medical and surgical in‐hospital setting showed that a basal‐bolus insulin strategy that applied higher total daily doses of insulin than the sliding scale insulin regimen might result in better short‐term glycaemic control but might also cause an increase in severe hypoglycaemic episodes (Cochrane Systematic Review)
Effect of metformin in addition to dietary and lifestyle advice for pregnant women who are overweight or obese: the GRoW randomised, double-blind, placebo-controlled trial
For pregnant women who are overweight or obese, metformin given in addition to dietary and lifestyle advice initiated at 10–20 weeks’ gestation does not improve pregnancy and birth outcomes (The Lancet Diabetes & Endocrinology)
24-Hour Blood Pressure-Lowering Effect of an SGLT-2 Inhibitor in Patients with Diabetes and Uncontrolled Nocturnal Hypertension: Results from the Randomized, Placebo-Controlled SACRA Study
Non-severely obese older diabetes patients with uncontrolled nocturnal hypertension showed significant BP reductions without marked reductions in glucose with the addition of empagliflozin to existing antihypertensive and antidiabetic therapy. Use of SGLT2 inhibitors in specific groups (e.g. those with nocturnal hypertension, diabetes, and high salt sensitivity) could help reduce the risk of heart failure and cardiovascular mortality (Circulation)
- 1
- 2
- 3
- …
- 172
- Next Page »
Glycosmedia is also available as an App: